Please ensure Javascript is enabled for purposes of website accessibility

A Double Failure of Alzheimer's Drugs

By Jim Crumly - Feb 10, 2020 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Lilly and Roche reported their latest disappointments in attempting to effectively treat Alzheimer's by attacking amyloid plaques.

Eli Lilly (LLY 4.39%) and Roche (RHHBY 0.91%) announced the failure of a trial for two monoclonal antibody drugs for Alzheimer's disease, throwing further doubt on the approach of treating the disease by attacking amyloid plaques in the brain.

The trial was conducted by Washington University and compared Lilly's solanezumab and Roche's gantenerumab with a placebo in patients that have a rare genetic mutation that causes early-onset Alzheimer's disease. The study was designed to see if the progression of cognitive decline in Alzheimer's could be slowed with anti-amyloid drugs if treatment was started very early in the course of the disease. Subjects in the trial were cognitively normal or only mildly impaired at the start of the trial, and were followed for a minimum of four years. Both companies reported that their drugs failed to meet the study's primary endpoints.

A toy rocket that's crashed.

Image source: Getty Images.

Lilly's solanezumab has been a serial disappointer. The drug failed last-stage trials in 2012 and 2016, and the company appeared ready to give up on it. But Lilly said Monday that it still plans to continue with another study of solanezumab in older patients who have evidence of amyloid plaques but who have not yet experienced the onset of cognitive decline.

Roche reported a clinical failure of another anti-amyloid drug a year ago, but also plans to continue studying gantenerumab in two clinical trials in the broader population of patients with Alzheimer's not directly caused by genetic mutations.

Investors in biotech Biogen (BIIB 3.40%) are watching these developments closely, as that company is planning on filing an application any day now for aducanumab, another anti-amyloid monoclonal antibody, despite less-than-convincing clinical evidence for the drug's efficacy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.11 (0.91%) $0.37
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$298.85 (4.39%) $12.58
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$199.65 (3.40%) $6.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.